Abstract
Background Individualized treatment decisions for patients with multiple myeloma (MM) requires accurate risk stratification that takes into account patient-specific consequences of genetic abnormalities and tumor microenvironment on disease outcome and therapy responsiveness.
Methods Previously, SYstems Genetic Network AnaLysis (SYGNAL) of multi-omics tumor profiles from 881 MM patients generated the mmSYGNAL network, which uncovered different causal and mechanistic drivers of genetic programs associated with disease progression across MM subtypes. Here, we have trained a machine learning (ML) algorithm on activities of mmSYGNAL programs within individual patient tumor samples to develop a risk classification scheme for MM that significantly outperformed cytogenetics, International Staging System, and multi-gene biomarker panels in predicting risk of PFS across four independent patient cohorts.
Results We demonstrate that, unlike other tests, mmSYGNAL can accurately predict disease progression risk at primary diagnosis, pre- and post-transplant and even after multiple relapses, making it useful for individualized dynamic risk assessment throughout the disease trajectory.
Conclusion mmSYGNAL provides improved individualized risk stratification that accounts for a patient’s distinct set of genetic abnormalities and can monitor risk longitudinally as each patient’s disease characteristics change.
Competing Interest Statement
NB is a co-founder and member of the Board of Directors of Sygnomics, Inc., which will commercialize the SYGNAL technology. AP and ST have equity stakes in Sygnomics, Inc. The terms of these arrangements have been reviewed and approved by ISB and Duke University in accordance with their conflict-of-interest policies. PB received institutional research support from Glycomimetics, Pfizer, Notable labs, and is an advisor to Accordant Health Services (CVS Caremark).
Funding Statement
This work was supported by a NCI-5R01AI141953-04 (N.S.B.), NSF1565166 (N.S.B.), NCI-5R01CA259469-02, NSF2042948. And Washington Research Foundation Funding (N.S.B.), a grant from the Brotman Baty Institute for Precision Medicine (UW) Catalytic Collaboration Grant (DGC and PSB), and a private donation to the University of Washington Foundation. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704 (PI Thomas Lynch, MD). The Multiple Myeloma Research Foundation generously made available the Interim Analysis 12 (IA12) version of the CoMMpass clinical trial data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IA12 and IA18 rnaSeq data can be obtained from the MMRF (https://themmrf.org). SCCA data can be requested from pbecker{at}coh.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data. Microarray data are available at: GSE19784, GSE24080 and GSE136337. IA12 and IA18 data can be requested from MMRF. SCCA data can be requested from pbecker{at}coh.org. Code. mmSYGNAL risk prediction models: https://github.com/baliga-lab/mmSYGNAL-risk-prediction-models mmSYGNAL (original code base): https://github.com/baliga-lab/miner MINER (updated interface): https://github.com/baliga-lab/miner3
https://github.com/baliga-lab/mmSYGNAL-risk-prediction-models
